Research Article
JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib
Table 5
Patient characteristics and JAK2 levels stratified by the presence of early molecular response groups.
| Variable | Early molecular response | | Present (n = 24) | Absent (n = 16) | p-Value |
| Age, years (mean ± SD) | 40 ± 12 | 40 ± 10 | 0.986 | Sex, n (%) | — | — | 0.792 | Male | 14 (58.3) | 10 (62.5) | — | Female | 10 (41.7) | 6 (37.5) | — | Spleen size, cm (mean ± SD) | 9 ± 3 | 7 ± 2 | 0.104 | Laboratory parameters, mean ± SD, or median (range) | Hemoglobin (g/dL) | 9.4 ± 2.1 | 9.5 ± 3.2 | 0.892 | White blood cells (/μL) | 100,150 (20,390–498,470) | 131,475 (33,000–344,130) | 0.456 | Peripheral blood basophils (%) | 1 (0–8) | 1 (0–7) | 0.836 | Eosinophils (%) | 1 (0–5) | 1 (0–5) | 0.614 | Platelet count (x103/μL) | 199 (31–803) | 462 (49–1,123) | 0.024 | Peripheral blood blasts (%) | 8 (4–19) | 9 (2–20) | 0.709 | Sokal risk groups, n (%) | — | — | 0.936 | Low (<0.8) | 10 (41.7) | 7 (43.8) | — | Intermediate (0.8–1.2) | 4 (16.6) | 3 (18.8) | — | High (>1.2) | 10 (41.7) | 6 (37.4) | — | Hasford risk groups, n (%) | — | — | 0.987 | Low (≤780) | 7 (29.2) | 5 (31.3) | — | Intermediate (781–1,480) | 9 (37.5) | 6 (37.4) | — | High (>1,480) | 8 (33.3) | 5 (31.3) | — | EUTOS risk groups, n (%) | — | — | 0.154 | Low risk (≤87) | 24 (100.0) | 14 (87.5) | — | High risk (>87) | 0 (0.0) | 2 (12.5) | — | JAK2 levels before imatinib treatment, median (range) | JAK2 gene (fold changes) | 14.35 (0.18–35.13) | 43.86 (9.78–100.40) | <0.001 | Phosphorylated JAK2 (U/mL) | 0.40 (0.03–0.90) | 0.80 (0.24–1.34) | 0.005 | Total JAK2 (pg/mL) | 61.07 (11.82–370.79) | 451.66 (45.98–2,291.00) | 0.002 | JAK2 levels after 3 months of imatinib treatment, median (range) | JAK2 gene (fold changes) | 0.70 (0.00–8.00) | 1.20 (0.00–39.00) | 0.422 | Phosphorylated JAK2 (U/mL) | 0.28 (0.01–1.10) | 0.80 (0.24–13.95) | 0.001 | Total JAK2 (pg/mL) | 23.17 (2.92–282.50) | 26.64 (5.49–461.89) | 0.804 |
|
|